Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. The company expects next quarter’s revenue to be around $4.88 billion, close to analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.
Shares of medical device company Boston Scientific (NYSE:BSX)
jumped 8.5% in the pre-market session after the company reported first quarter 2025 results that beat analysts' sales and EPS expectations. Organic sales growth topped the company's own forecast and was led by a 25.6% surge in its Cardiovascular segment, a signal that demand in its largest business is accelerating.
Looking ahead, its revenue guidance for next quarter exceeded Wall Street's estimates. Overall, we think this was a decent quarter with some key metrics above expectations.
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence.
Medical device company Merit Medical Systems (NASDAQ:MMSI)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
Medical device company Boston Scientific (NYSE:BSX) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. Guidance for next quarter’s revenue was better than expected at $4.88 billion at the midpoint, 2% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.
The Benzinga Stock Whisper Index highlights five stocks that saw higher than usual searches and a look at the potential catalysts surrounding the names.
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital.
The select few that can do all three for many years are often the ones that make you life-changing money.
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies navigate potential margin pressures and competitive shifts.
Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 medical devices & supplies - diversified earnings season.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
